Spermidine, Sleep and Autophagy: Part Three: What Autophagy Also Does

Abstract

Autophagy is described in consumer material as though it were self-evidently good — cellular housekeeping, clearing damaged proteins, renewal. Inducing it is the entire rationale for spermidine.

In 2024, a group at Macquarie University tested spermidine in zebrafish and mouse models of a neurodegenerative disease in which autophagy is impaired. Autophagy was induced, confirmed by protein measurement. In the mice, nothing improved. In healthy wild-type mice, motor performance got worse.

The follow-up found why, and the paper's title asks the question directly: induction of autophagy, but also apoptosis?

1.The Model

Maxinne Watchon, Amanda Wright, Angela Laird and colleagues work on Machado-Joseph disease, also called spinocerebellar ataxia type 3. It is a fatal inherited neurodegenerative condition caused by an expanded CAG repeat in the ATXN3 gene, producing an ataxin-3 protein prone to forming intraneuronal aggregates.

Protein quality control, including autophagy, is impaired in patients and in animal models of the disease. That makes it close to an ideal test case for an autophagy inducer: a condition where the pathway is demonstrably broken and the aggregates are demonstrably there.

This is a rare disease and a long way from anyone's supplement shelf. We include it because it is the study that tested the mechanism rather than assuming it.

2.The Zebrafish Result

Transgenic zebrafish larvae expressing the expanded ataxin-3 protein swam shorter distances than controls, as expected in a motor-impairment model.

Spermidine treatment induced autophagy and increased the distance the transgenic fish swam. On its own, that is a clean positive result and exactly what the hypothesis predicts.

3.The Mouse Result

The same intervention was given to the CMVMJD135 mouse model of the disease, administered in drinking water.

It produced no improvement in motor behaviour assays, no improvement in neurological testing, and no improvement in neuropathology.

And wild-type mice — healthy animals with no disease — treated with spermidine showed decreased rotarod performance compared with untreated controls.

This was not a failure of delivery. Immunoblot analysis of protein extracted from mouse cerebellar tissue found increased phospho-ULK1 in spermidine-treated animals, indicating that autophagy had indeed been induced. The mechanism engaged. The outcome did not follow, and in healthy animals it went the other way.

4.What Else Was Happening

Because the wild-type finding was unexpected, the team returned to zebrafish to look at what spermidine was doing beyond autophagy.

In addition to inducing autophagy, spermidine treatment also induced apoptosis — programmed cell death — particularly in wild-type animals.

The authors' conclusion is unusually direct for a paper of this kind: spermidine may not be therapeutically beneficial for this disease, and in fact warrants caution because of the potential negative side effects caused by induction of apoptosis.

That the effect was most visible in healthy animals is the part worth sitting with. In a system with accumulated damaged protein, upregulating degradation has something useful to do. In a system without it, the same upregulation appears to have found other targets.

5.What This Does and Does Not Show

It is a zebrafish and mouse study, in a rare monogenic disease, at doses that do not translate to a human supplement. It is not evidence that spermidine harms people, and we are not presenting it as such.

The species discrepancy inside the paper is also a warning against reading any single organism too confidently. Zebrafish improved; mice did not. Had the study stopped after the fish, it would have been published as a positive result.

What it does show is that autophagy induction is a manipulation with more than one consequence, and that the second consequence is more visible in healthy tissue than in damaged tissue. That is directly relevant to a compound sold to healthy people on the strength of the first consequence.

It also connects to the safety picture in Part One. SmartAge reported adverse events balanced between groups over twelve months, in 100 older adults, at 0.9 mg a day. That is genuine reassurance for that dose. It is not reassurance for doses several times higher, which is where the field is heading and where Part Four sits.

Editorial Comment

MindHeaven® uses no spermidine, no autophagy inducer, and no compound sold on this mechanism. We make no claim about any of them.

We publish this part because autophagy has become the most persuasive word in the longevity supplement vocabulary, and it is persuasive precisely because it sounds like a process rather than a promise. Nobody has to claim that a product improves memory if they can say it activates cellular renewal, and the reader supplies the rest.

Here is a study in which the mechanism was verified as working, in the disease it was best suited to, and the animals did not improve — while healthy animals given the same treatment performed worse. A mechanism is a hypothesis about why something might help. It is not evidence that it did.

Part Four closes the series with the trial now recruiting in Greifswald, which uses roughly seven times the SmartAge dose, measures sleep with electrodes rather than questionnaires, and includes a marker for whether the compound engaged its target at all.